Loading…
Apollomics, Inc. is projected to rise to $17.23 by 2027, a +24% move from its current price of $13.94. APLM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $13.33 | $13.92 | $14.54 | -0.12% |
| May 30 | $13.08 | $13.91 | $14.78 | -0.23% |
| May 31 | $12.89 | $13.89 | $14.97 | -0.35% |
| Jun 1 | $12.73 | $13.87 | $15.13 | -0.47% |
| Jun 2 | $12.58 | $13.86 | $15.26 | -0.59% |
| Jun 3 | $12.45 | $13.84 | $15.39 | -0.70% |
| Jun 4 | $12.33 | $13.83 | $15.50 | -0.82% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.33 | $13.83 | $15.50 | -0.82% |
| Week 2 | $11.67 | $13.71 | $16.12 | -1.63% |
| Week 3 | $11.16 | $13.60 | $16.58 | -2.43% |
| Week 4 | $10.73 | $13.49 | $16.95 | -3.23% |
| Week 5 | $10.36 | $13.38 | $17.28 | -4.02% |
| Week 6 | $10.03 | $13.27 | $17.56 | -4.81% |
| Week 7 | $9.73 | $13.16 | $17.81 | -5.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its product portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Apollomics, Inc. (APLM) trades with a current price of $14.09 and a market capitalization of $30.93M, ranking 4792. The stock sits in the Healthcare sector as a clinical-stage biopharmaceutical company. The near-term picture shows a stock price around the current level with a defined 30-day range and notable volatility.
A major floor 22.5% below — a decisive break under it would weaken the trend.
The nearest floor, 7.8% below — buyers have tended to step in here.
The nearest ceiling, 18.1% above — a clean break opens room to run.
A major ceiling 56.2% above — clearing it would confirm fresh momentum.
Key APLM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APLM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.99 | Sell | $14.08 | Sell |
| MA 10 | $14.13 | Sell | $14.21 | Sell |
| MA 20 | $14.60 | Sell | $14.40 | Sell |
| MA 50 | $15.12 | Sell | $15.30 | Sell |
| MA 100 | $17.51 | Sell | $16.08 | Sell |
| MA 200 | $16.33 | Sell | $16.62 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.26 | Neutral |
| Stoch RSI (14) | 31.18 | Neutral |
| CCI (20) | -50.81 | Neutral |
| Williams %R (14) | -82.53 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -9.77 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 17.47 | Buy |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -0.29 | Sell |
| Ultimate (7,14,28) | 35.76 | Neutral |
| Momentum (10) | -0.71 | Sell |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 13.97 | Sell |
| ADX (14) | 14.89 | Neutral |
| ATR (14) | 0.51 | Info |
The 30-day technical picture is neutral, with RSI at 50. The stock trades near its moving averages, with a SMA50 of $15.35 and a SMA200 of $16.25. Immediate support is at $12.85 and resistance at $16.47. The 30-day range runs from a low of $10.41 to a high of $19.06.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.85 | $13.94 | $18.16 | 0% | Neutral | |
| $12.89 | $17.23 | $24.78 | +24% | Bullish | |
| $14.18 | $19.84 | $30.06 | +42% | Bullish | |
| $13.36 | $19.44 | $30.67 | +39% | Bullish | |
| $13.43 | $20.24 | $33.04 | +45% | Bullish | |
| $12.32 | $19.19 | $32.26 | +38% | Bullish | |
| $11.59 | $18.61 | $32.12 | +34% | Bullish | |
| $12.33 | $20.39 | $36.03 | +46% | Bullish | |
| $13.84 | $23.56 | $42.53 | +69% | Bullish | |
| $17.01 | $29.76 | $54.82 | +113% | Bullish | |
| $14.21 | $28.30 | $56.63 | +103% | Bullish | |
| $28.36 | $63.02 | $141.91 | +352% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.85 | $13.94 | $16.51 | +0.00% |
| June 2026 | $11.30 | $13.44 | $16.48 | -3.62% |
| July 2026 | $10.39 | $12.53 | $15.69 | -6.77% |
| August 2026 | $10.45 | $12.73 | $16.21 | +1.66% |
| September 2026 | $10.49 | $12.90 | $16.63 | +1.30% |
| October 2026 | $9.88 | $12.25 | $15.97 | -5.05% |
| November 2026 | $9.94 | $12.40 | $16.34 | +1.29% |
| December 2026 | $10.86 | $13.65 | $18.16 | +10.05% |
Click any year to see its month-by-month APLM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The APLM price prediction for 2026 points to an average of $13.94 (low $12.85, high $18.16) — a potential gain of 0% on today's $13.94. A consolidation phase looks the most probable path here.
In 2027, APLM is projected to trade between $12.89 and $24.78, averaging $17.23 — a potential gain of +24% from today's $13.94. That is up +24% on the projected 2026 average. Momentum favours further upside here.
Apollomics, Inc.'s 2028 outlook centres on $19.84, within a $14.18 to $30.06 range. That is up +15% on the projected 2027 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, APLM could reach as high as $30.67, with a base case around $19.44 and support toward $13.36 — roughly +39% from $13.94. Momentum favours further upside here.
Expect APLM to range from $13.43 to $33.04 through 2030. The $20.24 average target implies a +45% move from current prices. That is up +4% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The APLM price prediction for 2031 points to an average of $19.19 (low $12.32, high $32.26) — a potential gain of +38% on today's $13.94. Momentum favours further upside here.
In 2032, APLM is projected to trade between $11.59 and $32.12, averaging $18.61 — a potential gain of +34% from today's $13.94. That is -3% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Apollomics, Inc.'s 2033 outlook centres on $20.39, within a $12.33 to $36.03 range. That is up +10% on the projected 2032 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2034, APLM could reach as high as $42.53, with a base case around $23.56 and support toward $13.84 — roughly +69% from $13.94. Buyers look set to stay in control over this stretch.
Expect APLM to range from $17.01 to $54.82 through 2035. The $29.76 average target implies a +113% move from current prices. That is up +26% on the projected 2034 average. Momentum favours further upside here.
The APLM price prediction for 2040 points to an average of $28.30 (low $14.21, high $56.63) — a potential gain of +103% on today's $13.94. Buyers look set to stay in control over this stretch.
In 2050, APLM is projected to trade between $28.36 and $141.91, averaging $63.02 — a potential gain of +352% from today's $13.94. That is up +123% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in APLM today (≈ 71.736011 APLM) could be worth
$4,520.49
+$3,520.49 (+352%) by 2050 · US Dollar
Based on the average projected APLM price of $63.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APLMwould be worth at today's price.
$1,000 invested in APLM on May 27, 2025 (≈ 152.9052 APLM) would be worth
$2,131.5
+$1,131.5 (+113.1%) today · 2.13× · US Dollar
Based on a APLM entry price of $6.54 vs. today's $13.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.52 | $1,030.68 | +3.1% |
| 1 month ago | $13.19 | $1,056.86 | +5.7% |
| 3 months ago | $20.39 | $683.84 | -31.6% |
| 6 months ago | $15.05 | $926.25 | -7.4% |
| 1 year ago | $6.54 | $2,131.5 | +113.1% |
| All time (4.5y) ago | $990 | $14.08 | -98.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APLM forecast.
Our base-case forecast reaches $28.00 around 2035.
Implied market cap at $28.00: $61.49M
The year-by-year forecast points to a bullish path beyond 2026. In 2026 the avg is $14.09 with a min of $12.85 and a max of $18.59 (ROI 0, sentiment NEUTRAL). From 2027 onward, the model projects stronger upside, with 2027 avg $17.23 (ROI 22.3) and 2028 avg $20.21 (ROI 43.5), followed by 2029 avg $19.73 (ROI 40.1) and 2030 avg $20.26 (ROI 43.8).
The longer horizon shows continued gains: 2031 avg $19.34 (ROI 37.3), 2032 avg $18.44 (ROI 30.9), 2033 avg $19.96 (ROI 41.7), 2034 avg $23.63 (ROI 67.8), 2035 avg $29.95 (ROI 112.7), 2040 avg $27.72 (ROI 96.8), and 2050 avg $62.94 (ROI 346.8). In sum, the outlook is bullish with meaningful upside potential over the coming years, but these are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030, the forecast shows an avg of $20.26 with min $13.17 and max $33.68; ROI 43.8; sentiment BULLISH.
Forecasts indicate a bullish path starting 2027, with rising averages and ROIs through 2050 (e.g., 2027 avg $17.23, 2028 avg $20.21, 2050 avg $62.94; ROI 22.3, 43.5, 346.8 respectively). See also the neutral stance for 2026.
Yes — the 2050 max is $144.75, which exceeds $100, indicating the possibility within the forecast horizon.
Current price is $14.09 and market cap is $30.93M.
The 30-day range is $10.41 to $19.06; 2026 forecast has min $12.85, avg $14.09, max $18.59 with ROI 0 and sentiment NEUTRAL.
Apollomics, Inc. Community Discussion
0Share your Apollomics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.